Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial

Blood (2025) 146 (Supplement 1): 3602.

https://doi.org/10.1182/blood-2025-3602

Published: 2025

Journal Articles

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Blood (2025) 146 (Supplement 1): 582.

https://doi.org/10.1182/blood-2025-582

Published: 2025

Journal Articles

Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL

Blood (2025) 146 (Supplement 1): 7408.

https://doi.org/10.1182/blood-2025-7408

Published: 2025

Journal Articles

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Blood (2025) 146 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2025-3885

Published: 2025

Journal Articles

Systematic molecular profiling to identify determinants of response to ibrutinib

Blood (2025) 146 (Supplement 1): 3881.

https://doi.org/10.1182/blood-2025-3881

Published: 2025

Journal Articles

Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL

Anja Rathgeber, Stacey Fernandes, Adi Nagler, Shuqiang Li, David Dorfman, Lars Bullinger, Matthew S Davids, Jennifer Brown, Kenneth Livak, Leif Ludwig, Catherine Wu, Livius Penter

Blood (2025) 146 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2025-3876

Published: 2025

Journal Articles

Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab

Blood (2025) 146 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2025-1812

Published: 2025

Journal Articles

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Blood (2025) 146 (Supplement 1): 664.

https://doi.org/10.1182/blood-2025-664

Published: 2025

Journal Articles

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

Jennifer Brown, Swetha Challagulla, David Campbell, Qianhong Fu, Wassim Aldairy, Keri Yang, Rhys Williams, Constantine Tam

Blood (2025) 146 (Supplement 1): 7443.

https://doi.org/10.1182/blood-2025-7443

Published: 2025

Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2025-2129

Published: 2025

Journal Articles

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

John Seymour, Andrew Aw, Vincent Ribrag, Guillaume Cartron, Arnon Kater, Ki-Seong Eom, Alan Skarbnik, Alessandra Tedeschi, Malgorzata Wach, Jing-Zhou Hou, Arpad Illes, Batul Suterwala, Jiefen Munley, Ellie John, Toshifumi Fujimori, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2025-2118

Published: 2025

Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Blood (2025) 146 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2025-2115

Published: 2025

Journal Articles

Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials

Inhye Ahn, Zunqiu Wang, Svitlana Tyekucheva, Kiyomi Mashima, Stacey Fernandes, Vanitha Ramakrishnan, Jessica Li, Linlin Xu, Rameen Beroukhim, Ignaty Leshchiner, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2113.

https://doi.org/10.1182/blood-2025-2113

Published: 2025

Journal Articles

Integrated single-cell RNA sequencing and TCR profiling identifies immune drivers of severe early toxicity in CLL patients treated with idelalisib

Saurabh Yadav, Lu Yang, Zunqiu Wang, Binu Kandathilparambil Sasi, Stacey Fernandes, John-Hanson Machado, Samantha Shupe, Ignaty Leshchiner, Lili Wang, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2025-2103

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Jennifer Brown, Robert Black, Hang Phan, Katherine Chapis, Samantha Pazienza, Sandra Re, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Lars van der Veen, Michael Lahn, Philippe Armand

Blood (2025) 146 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2025-3913

Published: 2025

Journal Articles

SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia

Fernanda Santos Azevedo, Kiyomi Mashima, Ava Bidgoli, Paulina Predko, Mariia Mikhaleva, Stephen Martindale, Stacey Fernandes, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Jennifer Brown

Blood (2025) 146 (Supplement 1): 3906.

https://doi.org/10.1182/blood-2025-3906

Published: 2025

Journal Articles

Characterization of IGHV subgroups and their prognostic relevance in CLL

Daniel Sungchul Choi, Uday Aditya Sarkar, Yue Ren, Yinglu Zhou, Roberta S. Azevedo, James Yoon, Kiyomi Mashima, Fernanda Santos Azevedo, Gordon Saksena, Stacey Fernandes, Paulina Predko, Matthew S Davids, Svitlana Tyekucheva, Jennifer Brown, Inhye Ahn

Blood (2025) 146 (Supplement 1): 3899.

https://doi.org/10.1182/blood-2025-3899

Published: 2025

Journal Articles

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Paolo Ghia, Barbara Eichhorst, Tomasz Wrobel, Inci Alacacıoğlu, Ana Rita da Fonseca, Dennis Carney, Guillaume Cartron, Alina Gerrie, Don Stevens, Marianne de Borja, Toshifumi Fujimori, Ellie John, L. Alex Liggett, Gary De Jesus, Veerendra Munugalavadla, Jennifer Brown

Blood (2025) 146 (Supplement 1): 3898.

https://doi.org/10.1182/blood-2025-3898

Published: 2025

Journal Articles

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial

Jennifer Brown, Timothy Victor, Alan Wu, Nicole Lamanna, Constantine Tam, Lugui Qiu, Rasika Korde, Tommi Salmi, Gisoo Barnes, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 711.

https://doi.org/10.1182/blood-2025-711

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Systematic molecular profiling to identify determinants of response to ibrutinib

Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL

Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials

Integrated single-cell RNA sequencing and TCR profiling identifies immune drivers of severe early toxicity in CLL patients treated with idelalisib

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia

Characterization of IGHV subgroups and their prognostic relevance in CLL

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only